Voyager also presented data on its Tau silencing gene therapy program intended for Alzheimer’s disease, which is advancing into later stages of research. Voyager’s lead antibody, VY-TAU01, targets pathological tau and has demonstrated robust preclinical activity. Experimental data shows that VY-TAU01 was not only well-tolerated but also exhibited favorable pharmacokinetics in non-human primates (NHPs).
Voyager Therapeutics has reiterated its commitment to addressing severe neurological diseases leveraging its novel AAV gene therapies. Their ongoing developments with the TRACER platform and other CNS gene therapy programs reflect the company’s technological demarcation in the gene therapy arena.
The rich data from these programs will aid in the progression of Voyager’s work towards their goal of pioneering the next generation of AAV therapies. However, the journey from preclinical data to clinical trials is typically long and complex, necessitating fastidious safety and efficacy evaluations. Therefore, while the resultant data from these programs is promising, additional research and investigations are necessary to accelerate these programs into clinical trials and subsequent therapeutic uses.
Comments